Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Southpoint Capital Advisors LP

Southpoint Capital Advisors LP lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 10.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 600,000 shares of the medical research company's stock after selling 69,976 shares during the period. Charles River Laboratories International makes up about 2.6% of Southpoint Capital Advisors LP's investment portfolio, making the stock its 21st largest position. Southpoint Capital Advisors LP owned about 1.17% of Charles River Laboratories International worth $110,760,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CRL. Optiver Holding B.V. purchased a new position in Charles River Laboratories International during the fourth quarter worth $37,000. GeoWealth Management LLC boosted its stake in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International during the fourth quarter worth $48,000. Tortoise Investment Management LLC boosted its stake in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares during the period. Finally, Huntington National Bank boosted its stake in Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after buying an additional 164 shares during the period. Institutional investors own 98.91% of the company's stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Up 0.3%

NYSE:CRL traded up $0.45 during mid-day trading on Thursday, reaching $135.43. The company's stock had a trading volume of 1,306,515 shares, compared to its average volume of 989,499. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The stock has a fifty day moving average of $133.64 and a 200-day moving average of $164.14. The firm has a market capitalization of $6.65 billion, a PE ratio of 902.89, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same period in the prior year, the firm earned $2.27 earnings per share. The firm's revenue for the quarter was down 2.7% compared to the same quarter last year. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on CRL shares. Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price for the company in a research note on Monday, March 3rd. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus target price of $172.31.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).